216 related articles for article (PubMed ID: 25610957)
1. Characterization of co-purified acellular pertussis vaccines.
Xu Y; Tan Y; Asokanathan C; Zhang S; Xing D; Wang J
Hum Vaccin Immunother; 2015; 11(2):421-7. PubMed ID: 25610957
[TBL] [Abstract][Full Text] [Related]
2. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
[TBL] [Abstract][Full Text] [Related]
3. Human Immune Responses to Pertussis Vaccines.
Ausiello CM; Mascart F; Corbière V; Fedele G
Adv Exp Med Biol; 2019; 1183():99-113. PubMed ID: 31342460
[TBL] [Abstract][Full Text] [Related]
4. Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.
Esposito S; Stefanelli P; Fry NK; Fedele G; He Q; Paterson P; Tan T; Knuf M; Rodrigo C; Weil Olivier C; Flanagan KL; Hung I; Lutsar I; Edwards K; O'Ryan M; Principi N;
Front Immunol; 2019; 10():1344. PubMed ID: 31333640
[TBL] [Abstract][Full Text] [Related]
5. Acellular pertussis vaccines and the role of pertactin and fimbriae.
Poolman JT; Hallander HO
Expert Rev Vaccines; 2007 Feb; 6(1):47-56. PubMed ID: 17280478
[TBL] [Abstract][Full Text] [Related]
6. Relationship of immunogenicity to protective potency in acellular pertussis vaccines.
Xing D; Asokanathan C; Xu YH; Bolgiano B; Douglas-Bardsley A; Zhang S; Wang J; Corbel M
Hum Vaccin Immunother; 2014; 10(7):2066-73. PubMed ID: 25424817
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
[TBL] [Abstract][Full Text] [Related]
8. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.
Meade BD; Lynn F; Reed GF; Mink CM; Romani TA; Deforest A; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):595-600. PubMed ID: 7659484
[TBL] [Abstract][Full Text] [Related]
9. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.
Bottero D; Gaillard ME; Errea A; Moreno G; Zurita E; Pianciola L; Rumbo M; Hozbor D
Vaccine; 2013 Oct; 31(45):5262-8. PubMed ID: 24012570
[TBL] [Abstract][Full Text] [Related]
10. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.
Gaillard ME; Bottero D; Errea A; Ormazábal M; Zurita ME; Moreno G; Rumbo M; Castuma C; Bartel E; Flores D; van der Ley P; van der Ark A; F Hozbor D
Vaccine; 2014 Feb; 32(8):931-7. PubMed ID: 24397896
[TBL] [Abstract][Full Text] [Related]
11. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
[TBL] [Abstract][Full Text] [Related]
12. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
Boros CA; Hanlon M; Gold MS; Roberton DM
Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
[TBL] [Abstract][Full Text] [Related]
13. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection.
Denoël P; Poolman J; Carletti G; Veitch K
Vaccine; 2002 Jun; 20(19-20):2551-5. PubMed ID: 12057612
[TBL] [Abstract][Full Text] [Related]
14. Pertussis vaccines and the challenge of inducing durable immunity.
Warfel JM; Edwards KM
Curr Opin Immunol; 2015 Aug; 35():48-54. PubMed ID: 26091979
[TBL] [Abstract][Full Text] [Related]
15. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
[TBL] [Abstract][Full Text] [Related]
16. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity.
Banus S; Stenger RM; Gremmer ER; Dormans JA; Mooi FR; Kimman TG; Vandebriel RJ
BMC Immunol; 2008 May; 9():21. PubMed ID: 18498620
[TBL] [Abstract][Full Text] [Related]
17. Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy.
Dirix V; Verscheure V; Goetghebuer T; Hainaut M; Debrie AS; Locht C; Mascart F
Vaccine; 2009 Oct; 27(43):6042-7. PubMed ID: 19665604
[TBL] [Abstract][Full Text] [Related]
18. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.
Littmann M; Hülsse C; Riffelmann M; Wirsing von König CH
Vaccine; 2008 May; 26(19):2344-9. PubMed ID: 18396360
[TBL] [Abstract][Full Text] [Related]
19. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
Denoël P; Godfroid F; Guiso N; Hallander H; Poolman J
Vaccine; 2005 Nov; 23(46-47):5333-41. PubMed ID: 16054273
[TBL] [Abstract][Full Text] [Related]
20. Outer membrane vesicles: an attractive candidate for pertussis vaccines.
Hozbor DF
Expert Rev Vaccines; 2017 Mar; 16(3):193-196. PubMed ID: 28010142
[No Abstract] [Full Text] [Related]
[Next] [New Search]
